Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA < 6 Million IU/mL

Aim Results of recent studies have confirmed the efficacy of an 8-week course of ledipasvir/sofosbuvir (LDV/SOF) in patients who are non-cirrhotics, native to treatment, are infected with hepatitis C (HCV) genotype 1, and have HCV viral load

Saved in:
Bibliographic Details
Published in:Digestive diseases and sciences 2018-12, Vol.63 (12), p.3480-3486
Main Authors: Yanny, Beshoy, Saab, Sammy, Durazo, Francisco, Latt, Nyan, Mitry, Amanda, Mikhail, Mira Moris, Hanna, Ramy M., Aziz, Antony, Sahota, Amandeep
Format: Article
Language:English
Subjects:
Age
Age Factors
Aged
Antiviral Agents - administration & dosage
Antiviral Agents - adverse effects
Antiviral drugs
Aspartate
Benzimidazoles - administration & dosage
Benzimidazoles - adverse effects
Biochemistry
California - epidemiology
Comparative analysis
Drug therapy
Female
Fluorenes - administration & dosage
Fluorenes - adverse effects
Gastroenterology
Genotype & phenotype
Geriatrics
Hepacivirus - drug effects
Hepacivirus - genetics
Hepatitis
Hepatitis C
Hepatitis C - diagnosis
Hepatitis C - drug therapy
Hepatitis C - epidemiology
Hepatitis C - virology
Hepatitis C virus
Hepatology
Humans
Liver cirrhosis
Male
Medicine
Medicine & Public Health
Middle Aged
Oncology
Original Article
Retrospective Studies
RNA
Sustained Virologic Response
Transplant Surgery
Treatment Outcome
Uridine Monophosphate - administration & dosage
Uridine Monophosphate - adverse effects
Uridine Monophosphate - analogs & derivatives
Viral Load - drug effects
Viral Load - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim Results of recent studies have confirmed the efficacy of an 8-week course of ledipasvir/sofosbuvir (LDV/SOF) in patients who are non-cirrhotics, native to treatment, are infected with hepatitis C (HCV) genotype 1, and have HCV viral load
ISSN:0163-2116
1573-2568
DOI:10.1007/s10620-018-5283-1